

### >> Fund Objective

This exchange-traded fund seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index<sup>SM</sup>.

### >> Fund Facts

Fund Ticker	FBT
CUSIP	33733E203
Intraday NAV	FBTIV
Fund Inception Date	6/19/06
Gross Expense Ratio <sup>^</sup>	0.56%
Net Expense Ratio	0.56%
Rebalance Frequency	Quarterly
Primary Listing	NYSE Arca

### >> Index Facts

Index Ticker	BTKTR
Index Inception Date	4/1/92

### >> Index Description

- >> The NYSE Arca Biotechnology Index<sup>SM</sup> is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
- >> Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.
- >> The index is rebalanced quarterly based upon closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent an approximately equal weight in the index.

### >> Performance Summary (%)

	Quarter	YTD	1 Year	3 Years	5 Years	10 Years	Since Inception
<b>Fund Performance*</b>							
Net Asset Value (NAV)	13.15	27.27	27.79	16.03	19.65	20.83	18.49
After Tax Held	13.15	27.27	27.79	16.03	19.63	20.82	18.44
After Tax Sold	7.79	16.15	16.45	12.62	16.06	18.13	16.21
Market Price	13.18	27.31	27.85	16.08	19.63	20.73	18.49
<b>Index Performance**</b>							
NYSE Arca Biotechnology Index <sup>SM</sup>	13.30	27.71	28.39	16.62	20.16	21.45	19.12
NASDAQ Biotechnology Index	11.20	14.69	10.34	7.05	12.29	16.80	14.90
S&P Composite 1500 Health Care Index	14.29	18.03	19.95	15.58	15.89	14.66	12.36
S&P 500 Index	7.71	10.56	17.91	17.31	13.95	11.97	9.49

### >> Calendar Year Total Returns (%)

	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	YTD
FBT	-18.33	44.87	36.90	-16.36	40.91	50.10	47.63	10.97	-19.60	36.99	27.27
NASDAQ Biotechnology Index	-12.30	15.96	16.04	12.09	32.29	66.02	34.40	11.77	-21.35	21.63	14.69
S&P Composite 1500 Health Care Index	-23.76	20.76	5.20	11.88	18.35	42.19	24.79	7.41	-2.05	22.47	18.03
S&P 500 Index	-37.00	26.46	15.06	2.11	16.00	32.39	13.69	1.38	11.96	21.83	10.56

### >> 3-Year Statistics

	Standard Deviation (%)	Alpha	Beta	Sharpe Ratio	Correlation
FBT	23.98	-9.16	1.68	0.72	0.65
NASDAQ Biotechnology Index	21.64	-16.16	1.57	0.39	0.67
S&P Composite 1500 Health Care Index	11.70	-1.62	1.02	1.24	0.81
S&P 500 Index	9.18	—	1.00	1.71	1.00

Overall Morningstar Rating™



Among 129 funds in the Health category.  
This fund was rated 3 stars/129 funds (3 years), 3 stars/120 funds (5 years), 4 stars/97 funds (10 years).<sup>s</sup>

*Performance data quoted represents past performance. Past performance is not a guarantee of future results and current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and shares when sold or redeemed, may be worth more or less than their original cost. You can obtain performance information which is current through the most recent month-end by visiting [www.ftportfolios.com](http://www.ftportfolios.com).*

<sup>^</sup>Expenses are capped contractually at 0.60% per year, at least until April 30, 2019.

\*NAV returns are based on the fund's net asset value which represents the fund's net assets (assets less liabilities) divided by the fund's outstanding shares. **After Tax Held** returns represent return after taxes on distributions. Assumes shares have not been sold. **After Tax Sold** returns represent the return after taxes on distributions and the sale of fund shares. Returns do not represent the returns you would receive if you traded shares at other times. **Market Price** returns are based on the midpoint of the bid/ask spread on the stock exchange on which shares of the fund are listed for trading as of the time that the fund's NAV is calculated. Returns are average annualized total returns, except those for periods of less than one year, which are cumulative. The fund's performance reflects fee waivers and expense reimbursements, absent which performance would have been lower. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor's tax situation and may differ from those shown. The after-tax returns shown are not relevant to investors who hold their fund shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts.

\*\*Performance information for the NYSE Arca Biotechnology Index<sup>SM</sup> is for illustrative purposes only and does not represent actual fund performance. Indexes do not charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown. Indexes are unmanaged and an investor cannot invest directly in an index.

## >> Portfolio Information

Number Of Holdings	30
Maximum Market Cap.	\$134.17 Billion
Median Market Cap.	\$9.66 Billion
Minimum Market Cap.	\$2.36 Billion
Price/Book	6.14
Price/Sales	8.08

## >> Top Holdings (%)

Nektar Therapeutics	3.24
Bio-Techne Corporation	2.91
Intercept Pharmaceuticals, Inc.	2.83
Neurocrine Biosciences, Inc.	2.82
Alnylam Pharmaceuticals, Inc.	2.75
IQIVA Holdings Inc.	2.71
Illumina, Inc.	2.70
Celgene Corporation	2.63
Regeneron Pharmaceuticals, Inc.	2.63
Seattle Genetics, Inc.	2.59

*You should consider the fund's investment objectives, risks, and charges and expenses carefully before investing. Contact First Trust Portfolios L.P. at 1-800-621-1675 or visit [www.ftportfolios.com](http://www.ftportfolios.com) to obtain a prospectus or summary prospectus which contains this and other information about the fund. The prospectus or summary prospectus should be read carefully before investing.*

## ETF Characteristics

The fund lists and principally trades its shares on the NYSE Arca, Inc.

The fund's return may not match the return of the NYSE Arca Biotechnology Index<sup>SM</sup>. Securities held by the fund will generally not be bought or sold in response to market fluctuations.

Investors buying or selling fund shares on the secondary market may incur customary brokerage commissions. Market prices may differ to some degree from the net asset value of the shares. Investors who sell fund shares may receive less than the share's net asset value. Shares may be sold throughout the day on the exchange through any brokerage account. However, unlike mutual funds, shares may only be redeemed directly from the fund by authorized participants, in very large creation/redemption units. If the fund's authorized participants are unable to proceed with creation/redemption orders and no other authorized participant is able to step forward to create or redeem, fund shares may trade at a discount to the fund's net asset value and possibly face delisting.

## Risk Considerations

The fund's shares will change in value, and you could lose money by investing in the fund. One of the principal risks of investing in the fund is market risk. Market risk is the risk that a particular stock owned by the fund, fund shares or stocks in general may fall in value. There can be no assurance that the fund's investment objective will be achieved.

The fund may invest in small capitalization and mid capitalization companies. Such companies may experience greater price volatility than larger, more established companies.

Biotechnology and pharmaceutical companies are subject to changing government regulation which could have a negative effect on the price, profitability and availability of their products and services. Biotechnology and pharmaceutical companies face increasing competition from generic drugs, termination of their patent protection and technological advances which render their products or services obsolete. The research and development costs required to bring a drug to market are substantial and may include a lengthy review by the government, with no guarantee that the product will ever be brought to market or show a profit. Many of these companies may not offer certain drugs or products for several years, and as a result, may have significant losses of revenue and earnings.

The NYSE Arca Biotechnology Index<sup>SM</sup> is a trademark of the NYSE Group, Inc. or its affiliates ("NYSE") and is licensed for use by First Trust. The fund is not sponsored or endorsed by NYSE. NYSE makes no representation or warranty, express or implied, to the owners of the fund or any member of the public regarding the advisability of investing in the fund or the ability of the fund to track the performance of the various sectors represented in the stock market. NYSE has no obligation to take the needs of the owners of the fund into consideration in determining, composing or calculating the Index. NYSE is not responsible for and has not participated in any determination or calculation made with respect to issuance or redemption of the fund.

§The Morningstar Rating<sup>TM</sup> for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The Morningstar Rating does not include any adjustment for sales loads. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. ©2018 Morningstar, Inc. All Rights Reserved. The Morningstar Rating<sup>TM</sup> information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

First Trust Advisors L.P. is the adviser to the fund. First Trust Advisors L.P. is an affiliate of First Trust Portfolios L.P., the fund's distributor.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA and the Internal Revenue Code. First Trust has no knowledge of and has not been provided any information regarding any investor. Financial advisors must determine whether particular investments are appropriate for their clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment risks independently and is responsible for exercising independent judgment with respect to its retirement plan clients.

## Definitions

**Standard Deviation** is a measure of price variability (risk). **Alpha** is an indication of how much an investment outperforms or underperforms on a risk-adjusted basis relative to its benchmark. **Beta** is a measure of price variability relative to the market. **Sharpe Ratio** is a measure of excess reward per unit of volatility. **Correlation** is a measure of the similarity of performance. The **NASDAQ Biotech Index** includes securities of NASDAQ-listed companies classified as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The **S&P Composite 1500 Health Care Index** is a capitalization-weighted index of companies classified by GICS as health care within the S&P Composite 1500 Index. The **S&P 500 Index** is an unmanaged index of 500 stocks used to measure large-cap U.S. stock market performance.